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ABSTRACT  
Aims C-reactive protein (CRP) and neutrophil count (NC) are important diagnostic indicators of 
inflammation. Point of care (POC) technologies for these markers are available but rarely used in 
community settings in the United Kingdom. To inform the potential for POC tests, it is necessary to 
understand the demand for testing. We aimed to describe the frequency of CRP and NC test requests 
from primary care to central laboratory services, describe variability between practices and assess the 
relationship between the tests. 
Methods We described the number of patients with either or both laboratory tests, and the volume of 
testing per individual and per practice, in a retrospective cohort of all adults in general practices in 
Oxfordshire, 2014-2016.  
Results 372,017 CRP and 776,581 NC tests in 160,883 and 275,093 patients respectively were 
requested from 69 practices. CRP was tested mainly in combination with NC, while the latter was 
more often tested alone. The median (IQR) of CRP and NC tests/person tested was 1 (1-2) and 2 (1-3) 
respectively.  The median (IQR) tests/practice/week was 36 (22-52) and 72 (50-108), and per 1,000 
persons registered/practice/ week was 4 (3-5) and 8 (7-9) respectively. The median (IQR) CRP and 
NC concentrations were 2.7 (0.9-7.9) mg/dl and 4.1 (3.1-5.5) x10
9
/L respectively. 
Conclusions The high demand for CRP and NC testing in the community, and the range of results 
falling within the reportable range for current POC technologies highlights the opportunity for 
laboratory testing to be supplemented by POC testing in general practice. 
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INTRODUCTION 
White blood cell count (WBC) and C-reactive protein (CRP) are the most commonly used markers of 
inflammation and infection in primary and secondary care.
1
 CRP is an acute-phase protein, normally 
present in the serum in low concentrations, that can rise rapidly in response to infectious and 
inflammatory conditions.
2
 Due to its wide availability and the relatively low costs of laboratory 
assays, CRP is the most used biomarker of inflammation.
3
 A raised WBC (leucocytosis), and 
particularly a raised neutrophil count (NC) (neutrophilia), are also used to assess the presence of 
abnormal inflammation which may be a result of an acute bacterial infection.
4,5
 Low NC, or 
neutropenia, can result from chemotherapy or disease modifying agents for auto-immune conditions, 
and can suggest increased risk of serious bacterial infection.
6
 
The value of CRP is largely attributable to its clinical usefulness as a triage test for inflammation or 
infection.
7
 Normal CRP concentrations are often helpful to exclude infectious or inflammatory 
diseases, whilst raised CRP concentrations can be helpful in alerting clinicians to an underlying 
disease process, interpreted in the context of specific symptoms. The National Institute for Health and 
Care Excellence (NICE) in the UK has recommended that CRP is used to guide decisions over 
antimicrobial therapy in primary care.
8
 However, as CRP is not a disease-specific marker, 
interpretation of borderline results can be challenging. There are a variety of indications for testing for 
WBC, some of which overlap with the indications of CRP testing, particularly in assessing potential 
infection. In the community, general practitioners (GPs) use CRP and NC for diagnosis, screening and 
monitoring of a number of diseases, including infections of possible bacterial aetiology and 
inflammatory conditions such as polymyalgia rheumatica and rheumatoid arthritis.
9
  
Several technologies currently offer point of care (POC) testing for CRP and WBC.
1,10
 Given that 
these tests are often used to assess acute presentations, receiving a result within minutes rather than 
waiting up to 24 hours for a central laboratory analysis to be communicated back to the GP, may 
improve processes of care and outcomes in community settings.
11–13
 It is therefore conceivable that in 
the future these tests could be moved fully into the community rather than performed by a central 
laboratory.  
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However, the volume of tests ordered in the community is poorly understood, as is the variability in 
demand across different GP practices and for different age groups. Furthermore, to our knowledge 
there is no report on the range of results from community samples, which is important for 
understanding the upper and lower values within which a POC tests needs to be accurate, in 
comparison to laboratory results.  
To assess the viability of the adoption of POC CRP and NC tests in primary care, a better 
understanding of their demand in the community and their range is needed. Therefore, with this study 
we aimed: to describe the frequency of requests for laboratory CRP and NC tests from the 
community, including the use of repeated tests and the likely demand per practice for testing 
capability; and to characterise the results of these tests and to describe the relationship between them. 
 
METHODS 
Study population and setting 
In a service evaluation approved by the Oxford University Hospitals (OUH) Foundation Trust Clinical 
Biochemistry Laboratory (CSS-BIO-1-4725), routinely collected, anonymised and de-identified data 
were initially available for a retrospective cohort of 442,637 patients of all ages in whom venous 
blood samples were taken and who had at least one request for either CRP or NC from primary care to 
the OUH Clinical Biochemistry Laboratory between 2014 and 2016. The database included age, sex, 
CRP and WBC results and date of request. Tests were requested from primary, secondary and tertiary 
healthcare settings.  
We restricted the analysis to adults (age ≥18 years), since children rarely have blood tests taken in 
primary care and so these data would not be representative of likely POC test demand. We also 
restricted the analysis to the 69 primary care practices in Oxfordshire whose main processor was the 
OUH laboratory, excluding those whose main processor was a laboratory outside Oxfordshire and 
those known to have closed or undergone major administrative reorganisation during the study period. 
A small number of instances when the test request location was unrecorded were also excluded. 
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CRP and NC measurements 
During the study period, CRP was initially analysed with immunoturbidimetry using the Siemens 
ADVIA 2400 analyser (Siemens Diagnostics, Frimley, UK) and from January 2015 using the Abbott 
Architect c16000 analyser (Abbott Diagnostics, Maidenhead, UK). Good agreement between the two 
methods has been demonstrated previously (Passing and Bablok regression: [Abbott CRP] = 0.13 + 
[0.99 Siemens CRP]).
14
 Between-batch precision of both methods was < 5% of the coefficient of 
variation (CV) at concentrations below 10 mg/L, and < 2% at higher concentrations. The reporting 
range was higher for the Abbott method (0.2 to 480 mg/L) than the Siemens method (0.1 to around 
150 mg/L). Test results below the lower limit of detection (0.1 and 0.2 mg/L: n=15,556 and n=11,524, 
respectively) and above the upper limit (150 and 480 mg/L: n=27 and n=26, respectively) were 
recoded to the value of the corresponding limit. 
Neutrophils were analysed as a component of the white cell differential count within the full blood 
count using the Sysmex Xn series haematology analysers (Sysmex UK and Ireland, Milton Keynes, 
UK). NC was expressed as a percentage of the WBC before March 2015, and in absolute values (x 
10
9
/L) subsequently. Values that were originally expressed as a percentage were converted to absolute 
values by multiplying the NC percentage by the absolute WBC and dividing by 100. 
 
Data analysis 
We computed the number of tests per person and per practice per week. We obtained the total number 
of adults and age-stratified number of patients registered at Oxfordshire GP practices from the NHS 
Digital website,
15
 and used them to calculate the number of tests per 1,000 persons per practice per 
week. The frequency distribution of these data and the test results were examined with histograms. 
Since these data were not normally distributed (skewed to the right), the median and interquartile 
range (IQR) were used to summarise them and nonparametric statistical methods were used. 
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We computed the number of CRP and NC tests performed and the number of patients who had either 
test, both tests, and only one of the tests ordered at the same time. We distinguished between patients 
who had a single CRP or NC in the study period, i.e. isolated tests, and patients that had tests repeated 
within 7 days. Some patients may have been included more than once if their tests were followed by 
another test within 7 days on more than one occasion. We used cumulative probability functions to 
show graphically the distribution of CRP and NC concentrations among patients with an isolated test, 
and those with a repeated test within 7 days. There were few examples of patients having a third test 
within a 7-day period so we did not analyse these.  
We also computed the proportion of patients with normal, mildly raised, elevated, and very high CRP 
(0-5, 5-50, 50-100, and ≥100 mg/L), and abnormally low, normal, mildly raised and elevated NC (0-2, 
2-7, 7-15, and ≥15 x 109 /L) test results as defined by the laboratory reference values and the NICE 
Guidance for the diagnosis and management of pneumonia in adults (100 mg/L cut-off for CRP). In 
addition, we cross-classified CRP and NC categories using contingency tables. We examined the 
relationship between CRP and NC using Spearman’s rank correlation and 95% confidence intervals 
(CI). 
All these statistics were calculated for all ages combined, and separately for adults (18-64 years), 
youngest old (65-84 years) and oldest old (85 years or more).  
All analyses were done in R version 3.5.
16
 Due to our large sample size, any statistical test ran to 
assess differences in CRP or NC concentrations between groups would appear statistically significant. 
We therefore decided not to use p-values.  
 
RESULTS 
The derivation and description of our study cohort is shown in Supplemental Figure 1. Out of the 
469,639 patients in the laboratory database who had requested a test, a total of 442,637 patients of all 
ages had either at least one CRP or NC test in the time period in any healthcare setting. After 
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appropriate exclusions, 372,017 CRP and 776,581 NC tests were available in 160,883 and 275,093 
patients, respectively. 
Table 1 shows the numbers of tests and patients and percentages with either or both tests. More NC 
tests were requested solely (421,761 tests, 53.1% of all occasions on which either test was ordered) 
than in combination with CRP (354,820 tests, 44.7% of all occasions on which either test was 
ordered). CRP test requests occurred far less commonly alone (17,197 tests, 2.2% of all occasions on 
which either test was ordered) than in combination with NC tests. In absolute terms, most of the 
testing was done in adults aged less than 65, but as a proportion of the total number of tests within 
each age group, the tests were more frequently requested in combination in the youngest (65-84) and 
oldest (85+) old than in adults aged less than 65 (60.4% and 64.9% vs. 55.1%, respectively).  
Table 2 summarises the number of tests per person, per practice per week and per 1,000 persons per 
practice per week, and the test results. The median (and IQR) number of tests per person in the time 
period in each age group was greater for NC than for CRP. An increase in the median number of tests 
per person from younger to older groups was seen for CRP but not for NC. The median (and IQR) 
number of tests per practice per week was larger for NC than for CRP. There was a large variation in 
the number of tests per practice per week, but much of this variation could be explained by practice 
size (R
2
=0.51), such that the median (IQR) number of CRP tests per 1,000 registered patients per 
week was 4 (3-5) for CRP and 8 (7-9) for NC 
Table 3 shows the pattern of tests results in all ages combined and across age groups. The proportion 
with a mildly raised (5–50 mg/L), elevated (50-100 mg/L) and very high (≥ 100 mg/L) CRP test result 
increased from younger to older age groups. No clear age-related trends were seen for NC test results 
in the normal range (2-7 x 10
9
/L), and the mildly raised range (7–15 x 109/L). However, the 
proportion with abnormally low (0-2 x 10
9
/L) NC test results decreased from younger to older age 
groups, while the proportion with elevated (≥15 x 109/L) NC test results increased from younger to 
older age groups. For patients whose NC was elevated (≥ 15 x 109/L) and who had also had a CRP 
test, the CRP was also elevated or very high in 52% (606/1159) in all adults and in 64% (153/240) in 
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the oldest age group. On the other hand, for patients whose CRP was elevated (50-100 mg/L) or very 
high (≥ 100 mg/L), the NC was in most cases within the normal range or mildly raised.  
A weak correlation (95% CI) between the test results was seen in all ages combined (0.392 (0.389-
0.395)). This was slightly weaker in the younger adults (0.363 (0.360-0.367)), and similar in the 
youngest old (0.384 (0.379-0.389)) and oldest old (0.374 (0.364-0.385)). 
Of all CRP tests, 97,836 were isolated single tests (26.3%), 8,375 (2.3%) were followed by another 
CRP test within 7 days, and the remaining 265,806 (71.4%) were repeated more than 7 days later. 
Figure 1 shows the distribution of CRP concentrations among those with isolated and those with 
repeated within 7 days CRP tests. Overall, those patients with repeated CRP tests within 7 days had 
higher CRP concentrations on both tests than those patients with isolated tests. This was more evident 
in the older than in the younger age groups. In general, CRP concentrations decreased from the first to 
the second test within 7 days. The magnitude of the reduction was larger in the youngest old (65-84) 
and the oldest old (85+) than in the younger adults (18-64). 
Of all NC tests, 118,853 were isolated single tests (15.3%), 18,570 NC tests (2.4%) were followed by 
another NC test within 7 days, and the remaining 639,158 NC tests (82.3%) were repeated more than 
7 days later. Figure 2 shows the distribution of NC concentrations among those with isolated and 
those with repeated within 7 days NC tests. Overall, those patients with repeated NC tests within 7 
days appeared to have higher NC concentrations than those patients with isolated tests. However, this 
difference was not more evident in the older age groups. There was only a small reduction in the NC 
from the first to the second test within 7 days. This reduction was not different across age groups. 
 
DISCUSSION 
In this retrospective cohort study of biomarkers of inflammation, we found that a large number of 
CRP and NC tests are requested from community settings. Between 2014 and 2016, a total of 372,017 
CRP and 776,581 NC laboratory tests were requested for adults in primary care in Oxfordshire, which 
served an adult population of 528,368 inhabitants in 2014.
17
 This corresponds roughly to one CRP test 
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per five people per year and one NC test per three people per year. In addition, while only around 2% 
would require a repeated test within 7 days, over 70% of those tested initially would require at least 
another CRP or NC test in a three-year period. 
The quantity of testing currently performed means there is an opportunity for CRP and NC POC 
testing to be introduced in the community. Previous work has indicated that POC testing in general 
has the potential to speed up diagnosis and treatment, avoid unnecessary referrals, improve outcomes, 
and increase doctor, device operator and patient satisfaction.
12,13
 More specifically, CRP may reduce 
antibiotic use in primary care when available within the timeframe of the prescribing decision,
18
 also 
in the UK.
19,20
 CRP has been recommended as a POC test in national guidance,
8
 and MedTech 
Innovation Briefings have been developed on two different CRP POC devices.
21,22
 Moreover, CRP 
and NC testing at the POC compared to laboratory testing has been suggested to be cost-effective.
23–25
 
However, more evidence on the cost-effectiveness of POC devices in the community is needed.
26,27
 
Considering laboratory-based testing of inflammatory markers now produce results that are outside 
the prescribing timeframe, reducing their usefulness in urgent decisions, the volume of point-of-care 
tests requested may be substantially higher than lab-based tests. 
To our knowledge, the most recent health technology assessment (HTA) on WBC and NC POC 
machines was conducted in 2013,
28
 and identified four different POC machines. Their analytical range 
is between 0.3 and 30 x 10
9
/L and they can yield results within 5 minutes. Capillary whole blood 
samples of around 10-15 μL are needed for measurement. The POC machines have shown high 
agreement (r ≥ 0.95), as well as low imprecision (CV ≤ 5%) in the low and high range, compared with 
laboratory assays measurements.
28–30
 However, these tests were evaluated mainly in hospital patients, 
which limits their generalizability to community settings.  
A more recent HTA on CRP POC devices used in primary care was conducted in January 2019, 
included fifteen different CRP POC devices.
31
 Their analytical range is in most cases of about 5 to 
200 mg/L and they can yield results within 5 to 10 minutes. Capillary whole blood samples of 
between 2.5-20 μL are needed for measurement. High correlations (r ≥ 0.95), as well as acceptable 
degree of imprecision (CV ≤ 10%) were reported for most of the devices, compared with reference 
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laboratory measurements. However, for high CRP concentrations, in some of the POC devices, the 
CVs were larger than 10%.
31
 POC testing performance may improve if advice and training from the 
local POC testing department is provided. Furthermore, internal quality control, external quality 
assurance, competence of testing, storage and display of the POC test results in the clinical record are 
important factors.
32
  
Of patients who received either a CRP or a NC test during the study period, only 5% received a CRP 
test without also a NC test in the 3 year period, whereas the opposite was not true, as 71% of the 
patients had had a NC test without a CRP test.  Unlike for the NC, for CRP we observed clear direct 
associations with age for the proportion of patients with a test, number of tests per person, test results, 
tests beyond the normal range, and reductions in test results between tests repeated within short 
periods of time. The correlation between CRP and NC in all ages combined was weak, and most 
patients with an elevated NC had also an elevated CRP concentration. Therefore as expected both 
tests would be required at point of care with one not able to substitute for both. 
With regards to test usage, the number of tests per 1,000 person, per practice, per week was twice as 
large for NC as for CRP, although the frequency of testing increased for both tests from younger to 
older age groups. Unlike for the NC, we observed that the proportion of patients who underwent a 
CRP test increased from younger to older age groups. Diagnosis in the older age groups may be more 
difficult because of non-specific presentations (such as absence of fever with infection)
33
 and general 
practitioners may be using CRP in addition to the NC to screen for serious illness.
9
 Potentially, the 
availability of portable CRP devices may be very beneficial in assisting the diagnosis in older frail or 
housebound patients whom access to blood tests is more challenging. However, evidence for the 
accuracy of CRP for the diagnosis of clinical conditions such as infection comes from emergency 
department and inpatient settings.
34–38
 Therefore, robust evidence applicable to community dwelling 
older adults is needed.  
In our population, CRP concentrations and the proportion of CRP test results that were elevated 
increased with age. This trend was not pronounced for the NC. This may be a reflection of a low-
grade chronic systemic inflammation occurring with age which may only be picked up by CRP 
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concentrations.
39,40
 Another explanation for this increase in CRP concentrations with age could be the 
increase in comorbidities which are associated with higher degree of inflammation such as 
cardiovascular disease or cancer.
41
 Finally, another reason for the increase with age in the proportion 
of elevated and very high CRP tests results may be better targeting of testing in older age groups. We 
have shown in those with repeated tests within 7 days that CRP decreases from the first to the second 
test, particularly in the oldest groups, while this is not so clearly seen for the NC. This decrease in 
CRP could for instance occur after an infection resolves either by itself or after treatment with 
antimicrobials.  
This study has some limitations. We could not obtain individual-level information about diagnosis 
and therapy to investigate how patterns of testing or test results may have guided the clinical 
diagnosis or to assess the influence of treatment on CRP concentrations and NC. Without further 
information on true inflammatory status, we could not explore further the reasons for the weak 
observed correlation between CRP concentrations and NC. We were therefore also unable to assess 
the appropriateness of the clinicians’ decisions to request laboratory tests, or how their decisions may 
have changed if POC testing had been available to guide prescribing decisions. During the study 
period there may have been population changes or changes in practice lists, although we would expect 
these to have only a small influence on our findings. Finally, although the study used comprehensive 
data in the region considered, it was restricted to a single English county and so results cannot 
automatically be extrapolated more widely. 
In conclusion, we have shown that CRP and NC are commonly used in the community, particularly in 
combination, with many patients requiring repeated tests, and that CRP use becomes increasingly 
more common in older adults. Demand for CRP and NC testing in the community largely increases in 
conjunction with practice size, and highlights the opportunity for laboratory testing to be 
supplemented by POC testing in primary care settings. 
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KEY MESSAGES 
 Laboratory C-Reactive Protein (CRP) and Neutrophil Count (NC) are important biomarkers 
of inflammation used by primary care practitioners 
 We described the patients with either or both tests, the volume of isolated and repeated 
testing, test results and their correlation, and variation across Oxfordshire primary care 
practices 
 The large demand of inflammatory markers laboratory testing from primary care practices 
highlights the opportunity for point of care testing to be implemented 
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Table 1 Test frequencies by age group.
1
  
 
      Adults 
(18-64) 
% 
Youngest old 
(65-84) 
% 
Oldest old 
(85+) 
% 
All ages 
(18+) 
% 
N with either test         
  N tests 482,719 100 259,443 100 51,616 100 793,778 100 
  N patients 191,783 100 70,345 100 14,198 100 276,326 100 
         
With both tests         
  N tests 211,856 43.9 121,582 46.9 21,382 41.4 354,820 44.7 
  N patients 105,758 55.1 42,488 60.4 9,216 64.9 157,462 57.0 
N with only a NC test         
  N tests 262,203 54.3 130,797 50.4 28,761 55.7 421,761 53.1 
  N patients 130,893 68.3 54,608 77.6 11,163 78.6 196,664 71.2 
N with only a CRP test         
  N tests 8,660 1.8 7,064 2.7 1,473 2.9 17,197 2.2 
  N patients 7,567 3.9 5,215 7.4 1,205 8.5 13,987 5.1 
         
With a NC test         
  N tests 474,059 98.2 252,379 97.3 50,143 97.1 776,581 97.8 
  N patients 190,950 99.6 70,026 99.5 14,117 99.4 275,093 99.6 
N with a CRP test         
  N tests 220,516 45.7 128,646 49.6 22,855 44.3 372,017 46.9 
  N patients 107,891 56.3 43,528 61.9 9,464 66.7 160,883 58.2 
Abbreviations: CRP – C-reactive protein; N – Number; NC – Neutrophil count. 
1
 The number of patients may not add up to the total because of double counting, for example if a patient visited the GP twice in the study period, in the first 
visit the GP requested CRP and a NC test, and in the second visit the GP requested only a neutrophil count.  
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Table 2 Number of CRP and NC tests per person, per GP practice per week, and test results. 
Median (IQR) Adults (18-64) Youngest old (65-84) Oldest old (85+) All ages (18+) 
CRP     
  N tests/person
 
1 (1-2) 1 (1-3) 2 (1-3) 1 (1-2) 
  N tests/practice/week
 
22 (14-29) 13 (7-19) 3 (1-4) 36 (22-52) 
  N tests/1,000 person/practice/week
 
3 (2-3) 9 (8-11) 12 (10-14) 4 (3-5) 
  Concentrations (mg/L)
 
2.0 (0.7-6.0) 3.6 (1.3-10.2) 5.2 (1.7-16.7) 2.7 (0.9-7.9) 
NC     
  N tests/person
 
2 (1-3) 2 (1-4) 2 (1-4) 2 (1-3) 
  N tests/practice/week
 
44 (28-61) 25 (13-37) 6 (3-9) 72 (50-108) 
  N tests/1,000 person/practice/week 6 (5-7) 19 (16-23) 27 (23-32) 8 (7-9) 
  Concentrations (x 10
9
/L)
 
4.0 (3.0-5.5) 4.1 (3.2-5.4) 4.6 (3.6-5.9) 4.1 (3.1-5.5) 
Abbreviations: CRP – C-reactive protein; N – Number; NC – Neutrophil count. 
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Table 3 Number and percentage of inflammatory tests requested at the same time by category of test 
result. 
 CRP (mg/L) 
Subsample 0-5  5-50  50-100  ≥100  Not assessed  Overall 
  NC (x 109/L) N tests %  N tests %  N tests %  N tests %  N tests %  N tests % 
Adults (18-64)                  
  0-2 9,492   1,582   50   13   12,145   23,282 4.93 
  2-7 132,555   45,591   1,720   727   207,266   387,859 82.16 
  7-15 5,234   6,851   934   926   37,793   51,738 10.96 
  ≥15 81   138   56   139   342   756 0.16 
  Not assessed 5,066   3,151   152   58   –   8,427 1.79 
  Overall 152,428 32.29  57,313 12.14  2,912 0.62  1,863 0.39  257,546 54.56  472,062 100 
Youngest old (65-84)                  
  0-2 2,846   918   53   37   5,163   9,017 3.45 
  2-7 65,097   36,025   2,395   939   116,028   220,484 84.41 
  7-15 4,247   7,351   1,471   1,461   9,289   23,819 9.12 
  ≥15 63   184   59   199   355   860 0.33 
  Not assessed 3,601   3,052   246   123   –   7,022 2.69 
  Overall 75,854 29.04  47,530 18.2  4,224 1.62  2,759 1.06  130,835 50.09  261,202 100 
Oldest old (85+)                  
  0-2 222   164   19   5   833   1,243 2.05 
  2-7 11,188   8,245   811   300   28,874   49,418 81.66 
  7-15 1,080   2,012   543   557   3,503   7,695 12.72 
  ≥15 24   63   31   122   170   410 0.68 
  Not assessed 696   869   111   72   –   1,748 2.89 
  Overall 13,210 21.83  11,353 18.76  1,515 2.50  1,056 1.75  33,380 55.16  60,514 100 
All ages (18+)                  
  0-2 12,560   2,664   122   55   18,141   33,542 4.23 
  2-7 208,840   89,861   4,926   1,966   352,168   657,761 82.86 
  7-15 10,561   16,214   2,948   2,994   50,585   83,252 10.49 
  ≥15 168   385   146   460   867   2,026 0.26 
  Not assessed 9,363   7,072   509   253   –   17,197 2.17 
  Overall 241,492 30.42  116,196 14.64  8,651 1.09  5,678 0.72  421,761 53.13  793,778 100 
Abbreviations: CRP – C-reactive protein; N – Number; NC – Neutrophil count. 
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Figure 1 Isolated versus repeated within 7 days CRP tests. The number of patients with isolated 
and repeated CRP tests within 7 days were 97,836 and 8,375 patients, respectively. X axes are on the 
logarithmic scale. 
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Figure 2 Isolated versus repeated within 7 days neutrophil count tests. The number of patients 
with isolated and repeated neutrophil count tests within 7 days were 118,853 and 18,570 patients, 
respectively. X axes are on the logarithmic scale. 
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Supplemental Figure 1 Flowchart of patient inclusion and exclusion. The total number of patients, 
tests, sex and age distribution, CRP and neutrophil count concentrations, are shown at each stage of 
inclusion/exclusion.  
The number of patients may not add up to the total as within the same study period, CRP test results 
for some patients may have been excluded when the patients were children, and included when the 
patients became adults. Similarly, CRP test results for same patients may have been excluded when 
they were requested from a non-primary care location, or included when from primary care locations. 
Analyses were restricted to the 69 primary care practices in Oxfordshire whose main processor was 
the OUH laboratory, excluding those whose main processor was a laboratory outside Oxfordshire and 
those known to have closed or undergone major administrative reorganisation during the study period. 
